Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 497 Neoplasms 302 Breast Neoplasms 294 Colorectal Neoplasms 228 Neoplasm Metastasis 194 Prostatic Neoplasms 175 Ovarian Neoplasms 173 Lung Neoplasms 159 Multiple Myeloma 158 Recurrence 131 Melanoma 125 Pancreatic Neoplasms 115 Squamous Cell Carcinoma of Head and Neck 104 Stomach Neoplasms 102 Leukemia, Myeloid, Acute 101 Endometrial Neoplasms 101 Small Cell Lung Carcinoma 88 Leukemia, Lymphocytic, Chronic, B-Cell 87 Triple Negative Breast Neoplasms 84 Lymphoma, Non-Hodgkin 84 Carcinoma, Renal Cell 83 Carcinoma, Hepatocellular 79 Urinary Bladder Neoplasms 77 Lymphoma, Large B-Cell, Diffuse 74 Lymphoma, Follicular 68 Advanced Solid Tumors 66 Lymphoma 62 Parkinson Disease 4, Autosomal Dominant Lewy Body 61 Glioblastoma 58 Head and Neck Neoplasms 56

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Anal Cancer Metastatic × 90 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡